 |
 |
E-MOVE reports from the 14th International Congress on Parkinson's Disease, Helsinki July 28-Aug 1. Poster and Platform session numbers refer to those in the abstract book, published in Parkinsonism and Related Disorders 2001;7(Supplement). Mixed Results from Rotigotine Patch (PD Congress 2001) 1. Rotigotine transdermal system (SPM-962) is safe and effective as monotherapy in early Parkinson's disease (PD) S Fahn, Parkinson's Study Group P-TU-181 2. Rotigotine transdermal delivery system (TDS) (SPM 962): A multicenter, double-blind, randomized placebo-controlled trial to assess the safety and efficacy of rotigotine TDS in patients with advanced Parkinson's disease N Quinn, SP 511 Investigators P-TU-223 These two randomized double-blind trials studied the dopamine agonist rotigotine, applied via a transdermal patch changed daily. Each trial used a 4-5 week titration phase and a 7-week maintenance phase. In the Fahn study, doses ranged from 4.5-18.0 mg/day, and in the Quinn study, from 9-27 mg/day. Approximately 85% of all patients completed the trial in both studies. Mild skin reactions were seen in both treated and placebo patients. In the Fahn study, nausea and vomiting were more common among treated patients, while in the Quinn study, they were more common among placebo patients. In the Fahn study, the primary outcome variable was UPDRS ADL and motor score change. Improvements over placebo in the four dosage groups were 4.5 mg-1.4 units (NS); 9.0 mg-2.6 units (p=0.06); 13.5 mg-5.1 units (p=0.0004); 18.0 mg-5.2 units (p=0.0002). In the Quinn study, the primary outcome variable was reduction in off time. Patients in the 18 mg/day group had a reduction in off time of 1.72 hours/day, and those in the 27 mg/day group had a 2.44 hours/day reduction. However, a strong and sustained placebo response resulted in no statistically significant difference between placebo and treated patients. --- Funding for E-MOVE meeting reports is provided in part by unrestricted educational grants from Allergan Inc., Elan Pharmaceuticals, and Pharmacia Corporation. ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn